Genetic Testing
MeDIP Sequencing and Analysis
MeDIP-seq for research profiling of methylated DNA enrichment; it is not a cancer screen, absolute methylation measurement or treatment test.
About this service
MeDIP-seq enriches methylated DNA fragments using an antibody and sequences the enriched material to study methylation patterns. Enrichment is not a base-by-base absolute methylation measurement; resolution and interpretation depend on the assay, controls, sample and analysis. This listing does not diagnose cancer or another condition.
Service highlights
- Research method based on methylated-DNA immunoprecipitation and sequencing.
- Can profile relative enrichment patterns in an agreed project.
- Does not establish absolute methylation at every base or clinical risk.
Who may consider it
- Epigenomics researchers.
- Laboratories studying DNA methylation patterns.
What to expect
Confirm current project availability and quote. Clarify accepted DNA/sample input and whether immunoprecipitation, library preparation, sequencing, analysis, controls and QC are included. Confirm output resolution, files and turnaround; no current sample SOP is supplied.
Scope and limitations
MeDIP-seq produces enrichment-based methylation data, not a clinical cancer marker, absolute site-level methylation score or diagnostic result. Findings do not establish disease risk, causation or treatment response.
Frequently asked questions
What does MeDIP-seq do?
It enriches methylated DNA fragments and sequences them to profile methylation patterns for research.
Does it provide absolute methylation at each base?
No. MeDIP-seq is enrichment-based and its resolution differs from base-resolution bisulfite methods.
Can it diagnose cancer or guide treatment?
No clinical diagnostic or treatment use is established. Confirm current project availability, workflow and quote.